SCHEMBL14883176

SCHEMBL14883176

CC(C)c1cccc(F)c1-n1nccn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 5/20 0.42
ANPEP P15144 5/20 0.42
HCRTR1 O43613 6/20 0.38
HCRTR2 O43614 5/20 0.38
CYP1A2 P05177 2/20 0.38
KCNH2 Q12809 1/20 0.38
NR1H2 P55055 1/20 0.37
NR1H3 Q13133 1/20 0.37
TSHR P16473 2/20 0.36
FAAH O00519 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
LMNA P02545 1/20 0.36
CYP3A4 P08684 1/20 0.36
GABRA1 P14867 1/20 0.36
HPGD P15428 1/20 0.36
GABRB1 P18505 1/20 0.36
GABRG2 P18507 1/20 0.36
PTGS1 P23219 1/20 0.36
SLC6A2 P23975 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14883248 0.80 TSHR (0.48) DPP4ANPEPHCRTR1HCRTR2CYP1A2
SCHEMBL14886142 0.76 ACHE (0.43) HCRTR1HCRTR2CYP1A2KCNH2CYP3A4
SCHEMBL22040918 0.75 NOTUM (0.43) DPP4ANPEPHCRTR1HCRTR2CYP1A2
SCHEMBL18594639 0.72 HCRTR1 (0.46) HCRTR1HCRTR2CYP1A2KCNH2
SCHEMBL14883121 0.71 HCRTR1 (0.38) HCRTR1HCRTR2
SCHEMBL18195995 0.71 CA2 (0.36) HCRTR1HCRTR2CYP1A2KCNH2TSHR
SCHEMBL12862574 0.69 FAAH (0.48) DPP4HCRTR1HCRTR2CYP1A2NR1H2
SCHEMBL19732402 0.69 GABRA1 (0.38) DPP4HCRTR1HCRTR2CYP1A2NR1H2
SCHEMBL16025392 0.69 HCRTR1 (0.49) HCRTR1HCRTR2CYP1A2KCNH2
SCHEMBL16031729 0.68 ERN1 (0.47) HCRTR1HCRTR2CYP1A2KCNH2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020065614-A1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2020-04-02 WO disclosed
US-9156819-B2 2-pyridyloxy-4-nitrile orexin receptor antagonists MERCK SHARP & DOHME CORP. (US) 2015-10-13 US disclosed
US-9156819-B2 2-pyridyloxy-4-nitrile orexin receptor antagonists MERCK SHARP & DOHME CORP. (US) 2015-10-13 US disclosed
US-20130102619-A1 2-PYRIDYLOXY-4-NITRILE OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME LLC 2013-04-25 US disclosed
US-20130102619-A1 2-PYRIDYLOXY-4-NITRILE OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME LLC 2013-04-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130102619-A1 2-PYRIDYLOXY-4-NITRILE OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, NTSR2 DPP4 854/4885ANPEP 1118/4885HCRTR1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.